You are now leaving hcp.osphena.com and proceeding to Osphena.ca

Osphena.ca is intended for Canadian healthcare professionals. If you are a Canadian healthcare professional, click “I Agree” to continue.

I Agree

Osphena® is affordable and accessible Several Ways For Patients to Save on Osphena®

Osphena® is affordable and accessible Several Ways For Patients to Save on Osphena®

Help your patients save through Osphena® Savings Programs

Patients with commercial insurance pay as little as $35 for 30 tablets or $90 for 90 tablets.

Savings options are also available for patients who do not have prescription insurance or whose insurance does not cover Osphena®.

Learn more about Osphena® Savings Options

Hypothetical Healthcare Professional.
Option 1

Immediate* access
Through their retail pharmacies with the Osphena® CoPay savings card:

Download Savings Card

Patients without prescription insurance, or whose insurance does not cover Osphena®, pay only $75 for 30 tablets or $190 for 90 tablets through a retail pharmacy.

*Applies only to pharmacies that have Osphena® in stock. Some pharmacies may need to order Osphena®. Immediate access is not guaranteed; delays are pharmacy-specific and beyond the control of Duchesnay USA.

ic savings white
Option 2

Discreet free home delivery
With Osphena At Home® 

Simply prescribe Osphena® through Osphena At Home® and patients receive free home delivery†, plus additional services including:

  • On-staff pharmacists to answer product questions
  • Assistance with insurance benefits verification
  • Monthly refill reminders.

Cash-paying patients, Medicare patients who elect to pay cash and commercially insured patients who are not covered for Osphena® pay only $75 for 30 tablets or $190 for 90 tablets.

3 easy ways to prescribe through Osphena At Home®:

  1. Call (844) 716-HOME (4663)
  2. Fax form to (844) 375-3010 or email it to This email address is being protected from spambots. You need JavaScript enabled to view it.
  3. ePrescribe: NCPDP 3685508; NPI 1487163598

Prescribing Instructions

Indication and Important Safety Information including Boxed Warning

INDICATIONS:

OSPHENA (ospemifene) is indicated for:

  • The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
  • The treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause.

Important Safety Information for OSPHENA

WARNING: ENDOMETRIAL CANCER and CARDIOVASCULAR DISORDERS

See full prescribing information for complete boxed warning

Endometrial Cancer

OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has estrogen agonistic effects. There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adequate diagnostic measures, including directed and random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding

Cardiovascular Disorders

Estrogen-alone therapy has an increased risk of stroke and deep vein thrombosis (DVT). OSPHENA 60 mg had cerebral thromboembolic and hemorrhagic stroke incidence rates of 1.13 and 3.39 per thousand women years, respectively vs. 3.15 and 0 per thousand women years, respectively with placebo. For deep vein thrombosis the incidence rate for OSPHENA 60 mg is 2.26 per thousand women years (2 reported cases) vs. 3.15 per thousand women years (1 reported case) with placebo.

CONTRAINDICATIONS

  • Undiagnosed abnormal genital bleeding
  • Known or suspected estrogen-dependent neoplasia
  • Active deep vein thrombosis (DVT), pulmonary embolism (PE), or a history of these conditions
  • Active arterial thromboembolic disease (e.g., stroke and myocardial infarction) or a history of these conditions
  • Hypersensitivity (e.g., angioedema, urticaria, rash, pruritus) to OSPHENA or any of its ingredients
  • OSPHENA is contraindicated in women who are or may become pregnant. OSPHENA may cause fetal harm when administered to a pregnant woman.

WARNINGS AND PRECAUTIONS

Cardiovascular Disorders

Risk factors for cardiovascular disorders, arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VYE) (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus), should be managed appropriately.

If feasible, OSPHENA should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism or during periods of prolonged immobilization.

Malignant Neoplasms

Endometrial Cancer

OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has agonistic effects.

An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The greatest risk appears to be associated with prolonged use and estrogen dose. Adding a progestin to postmenopausal estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer.

Breast Cancer

OSPHENA 60 mg has not been adequately studied in women with breast cancer; therefore, it should not be used in women with known or suspected breast cancer.

Severe Hepatic Impairment

OSPHENA should not be used in women with severe hepatic impairment.

Adverse Reactions

The most common adverse reactions (> 1%) include: hot flush, vaginal discharge, muscle spasms, headache, hyperhidrosis, vaginal hemorrhage, night sweats.

Drug interactions:

  • Do not use estrogens or estrogen agonist/antagonist concomitantly with OSPHENA
  • Do not use fluconazole or ketoconazole concomitantly with OSPHENA
  • Do not use rifampin concomitantly with OSPHENA. Rifampin decreases serum concentrations of OSPHENA.

Co-administration of OSPHENA with drugs that inhibit CYP3A4 and CYP2C9 may increase the risk of OSPHENA-related adverse reactions. OSPHENA is highly protein-bound. Use cautiously with highly protein-bound drugs as use with other highly protein-bound drugs may lead to increased exposure of that drug or ospemifene.

Please see Full Prescribing Information for OSPHENA (ospemifene) tablets, including Boxed Warning, regarding Endometrial Cancer and Cardiovascular Disorders, and Patient Information at osphena.com/hcp.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION:

OSPHENA (ospemifene) is indicated for:

  • The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
  • The treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause

Important Safety Information for OSPHENA

WARNING: ENDOMETRIAL CANCER and CARDIOVASCULAR DISORDERS

Endometrial Cancer

OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has estrogen agonistic effects. There is a potential increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adequate diagnostic measures, including directed and random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

Cardiovascular Disorders

In clinical trials for OSPHENA (duration of treatment up to 15 months), the incidence rates of thromboembolic and hemorrhagic stroke were 1.13 and 3.39 per thousand women years, respectively, in the OSPHENA 60 mg treatment group and 3.15 and 0 with placebo. The incidence of DVT was 2.26 per thousand women years (2 reported cases) in the OSPHENA 60 mg treatment group and 3.15 per thousand women years (1 reported case) with placebo. OSPHENA should be prescribed for the shortest duration consistent with treatment goals and risks for the individual woman.

There is a reported increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) who received daily oral conjugated estrogens (CE) [0.625 mg]-alone therapy over 7.1 years as part of the Women’s Health Initiative (WHI).

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION:

OSPHENA (ospemifene) is indicated for:

  • The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
  • The treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause

Important Safety Information for OSPHENA

WARNING: ENDOMETRIAL CANCER and CARDIOVASCULAR DISORDERS

Endometrial Cancer

OSPHENA is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, OSPHENA has estrogen agonistic effects. There is a potential increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adequate diagnostic measures, including directed and random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

Cardiovascular Disorders

In clinical trials for OSPHENA (duration of treatment up to 15 months), the incidence rates of thromboembolic and hemorrhagic stroke were 1.13 and 3.39 per thousand women years, respectively, in the OSPHENA 60 mg treatment group and 3.15 and 0 with placebo. The incidence of DVT was 2.26 per thousand women years (2 reported cases) in the OSPHENA 60 mg treatment group and 3.15 per thousand women years (1 reported case) with placebo. OSPHENA should be prescribed for the shortest duration consistent with treatment goals and risks for the individual woman.

There is a reported increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) who received daily oral conjugated estrogens (CE) [0.625 mg]-alone therapy over 7.1 years as part of the Women’s Health Initiative (WHI).